 John Carroll
Concepts (506)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transcatheter Aortic Valve Replacement | 54 | 2024 | 172 | 13.080 |
Why?
| | Foramen Ovale, Patent | 36 | 2025 | 50 | 11.160 |
Why?
| | Cardiac Catheterization | 59 | 2025 | 584 | 10.530 |
Why?
| | Aortic Valve Stenosis | 46 | 2024 | 298 | 8.960 |
Why?
| | Coronary Angiography | 34 | 2020 | 345 | 6.090 |
Why?
| | Heart Valve Prosthesis Implantation | 25 | 2023 | 199 | 6.010 |
Why?
| | Septal Occluder Device | 22 | 2025 | 50 | 5.660 |
Why?
| | Stroke | 36 | 2025 | 1119 | 4.980 |
Why?
| | Heart Valve Prosthesis | 20 | 2022 | 132 | 4.960 |
Why?
| | Echocardiography, Three-Dimensional | 13 | 2025 | 53 | 4.720 |
Why?
| | Echocardiography, Transesophageal | 19 | 2025 | 104 | 4.600 |
Why?
| | Aortic Valve | 36 | 2024 | 431 | 4.020 |
Why?
| | Heart Septal Defects, Atrial | 11 | 2020 | 57 | 3.510 |
Why?
| | Mitral Valve | 16 | 2023 | 101 | 3.410 |
Why?
| | Imaging, Three-Dimensional | 25 | 2019 | 563 | 3.340 |
Why?
| | Registries | 36 | 2024 | 1934 | 3.280 |
Why?
| | Mitral Valve Insufficiency | 12 | 2023 | 79 | 3.140 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 16 | 2019 | 109 | 3.080 |
Why?
| | Radiography, Interventional | 13 | 2020 | 114 | 3.040 |
Why?
| | Ultrasonography, Interventional | 12 | 2025 | 140 | 2.920 |
Why?
| | Heart Valve Diseases | 14 | 2019 | 170 | 2.640 |
Why?
| | Secondary Prevention | 13 | 2024 | 238 | 2.440 |
Why?
| | Treatment Outcome | 80 | 2025 | 10341 | 2.340 |
Why?
| | Echocardiography, Doppler, Color | 8 | 2019 | 43 | 2.050 |
Why?
| | Embolism, Paradoxical | 8 | 2024 | 8 | 1.810 |
Why?
| | Angioplasty, Balloon, Coronary | 13 | 2010 | 152 | 1.640 |
Why?
| | Heart Defects, Congenital | 8 | 2020 | 757 | 1.580 |
Why?
| | Fluoroscopy | 10 | 2021 | 170 | 1.570 |
Why?
| | Cardiac Surgical Procedures | 8 | 2023 | 504 | 1.490 |
Why?
| | Humans | 201 | 2025 | 130305 | 1.470 |
Why?
| | Heart Diseases | 6 | 2025 | 358 | 1.410 |
Why?
| | Prosthesis Implantation | 6 | 2019 | 149 | 1.410 |
Why?
| | Coronary Artery Disease | 11 | 2011 | 697 | 1.370 |
Why?
| | Cardiology | 13 | 2023 | 281 | 1.340 |
Why?
| | Thoracic Surgery | 10 | 2021 | 133 | 1.220 |
Why?
| | Stents | 17 | 2011 | 523 | 1.210 |
Why?
| | Catheterization | 8 | 2010 | 178 | 1.200 |
Why?
| | Coronary Vessels | 11 | 2010 | 254 | 1.180 |
Why?
| | Predictive Value of Tests | 20 | 2019 | 1974 | 1.170 |
Why?
| | Iatrogenic Disease | 3 | 2018 | 58 | 1.130 |
Why?
| | Heart Injuries | 4 | 2018 | 39 | 1.120 |
Why?
| | Prostheses and Implants | 6 | 2013 | 141 | 1.110 |
Why?
| | Cineangiography | 7 | 2009 | 16 | 1.100 |
Why?
| | Risk Factors | 41 | 2024 | 9865 | 1.050 |
Why?
| | Hypoxia | 4 | 2020 | 1075 | 1.030 |
Why?
| | Image Enhancement | 3 | 2013 | 166 | 1.020 |
Why?
| | Ischemic Attack, Transient | 4 | 2024 | 65 | 1.000 |
Why?
| | Societies, Medical | 9 | 2020 | 768 | 0.990 |
Why?
| | Aged, 80 and over | 37 | 2024 | 7128 | 0.970 |
Why?
| | Image Processing, Computer-Assisted | 8 | 2015 | 745 | 0.960 |
Why?
| | Mitral Valve Stenosis | 4 | 2016 | 22 | 0.960 |
Why?
| | Radiation Dosage | 8 | 2016 | 162 | 0.960 |
Why?
| | Aged | 65 | 2025 | 22282 | 0.960 |
Why?
| | Platelet Aggregation Inhibitors | 10 | 2024 | 454 | 0.950 |
Why?
| | Prosthesis Failure | 5 | 2020 | 124 | 0.940 |
Why?
| | Coronary Stenosis | 4 | 2010 | 43 | 0.930 |
Why?
| | Male | 97 | 2025 | 63748 | 0.920 |
Why?
| | Prosthesis Design | 13 | 2019 | 322 | 0.890 |
Why?
| | Sodium Chloride | 2 | 2015 | 142 | 0.880 |
Why?
| | Fibrinolytic Agents | 6 | 2022 | 264 | 0.840 |
Why?
| | Contrast Media | 6 | 2015 | 392 | 0.830 |
Why?
| | Percutaneous Coronary Intervention | 2 | 2020 | 480 | 0.810 |
Why?
| | Female | 90 | 2025 | 68842 | 0.810 |
Why?
| | Intracranial Embolism | 1 | 2022 | 32 | 0.800 |
Why?
| | Multimodal Imaging | 3 | 2020 | 111 | 0.800 |
Why?
| | United States | 44 | 2024 | 14110 | 0.790 |
Why?
| | Tomography, X-Ray Computed | 9 | 2020 | 2551 | 0.770 |
Why?
| | Technology Transfer | 1 | 2021 | 12 | 0.750 |
Why?
| | Patient Selection | 11 | 2024 | 678 | 0.750 |
Why?
| | Randomized Controlled Trials as Topic | 11 | 2024 | 1381 | 0.720 |
Why?
| | Time Factors | 20 | 2022 | 6615 | 0.720 |
Why?
| | Device Removal | 4 | 2012 | 143 | 0.700 |
Why?
| | Risk Assessment | 17 | 2021 | 3310 | 0.680 |
Why?
| | Migraine Disorders | 5 | 2024 | 91 | 0.680 |
Why?
| | Embolism | 3 | 2019 | 44 | 0.680 |
Why?
| | Computed Tomography Angiography | 3 | 2020 | 117 | 0.670 |
Why?
| | Surgery, Computer-Assisted | 4 | 2009 | 76 | 0.650 |
Why?
| | Echocardiography | 9 | 2020 | 640 | 0.640 |
Why?
| | Coronary Occlusion | 1 | 2019 | 19 | 0.640 |
Why?
| | Mitral Valve Annuloplasty | 1 | 2019 | 5 | 0.630 |
Why?
| | Middle Aged | 48 | 2025 | 31322 | 0.630 |
Why?
| | Lacerations | 1 | 2019 | 30 | 0.630 |
Why?
| | Postoperative Complications | 11 | 2021 | 2511 | 0.630 |
Why?
| | Product Surveillance, Postmarketing | 4 | 2015 | 65 | 0.620 |
Why?
| | Dyspnea | 1 | 2020 | 236 | 0.610 |
Why?
| | Shock, Cardiogenic | 1 | 2019 | 61 | 0.610 |
Why?
| | Technology Assessment, Biomedical | 2 | 2015 | 31 | 0.600 |
Why?
| | Atrial Fibrillation | 4 | 2020 | 383 | 0.590 |
Why?
| | Radiographic Image Enhancement | 5 | 2009 | 58 | 0.590 |
Why?
| | Balloon Occlusion | 3 | 2014 | 37 | 0.580 |
Why?
| | Thrombosis | 4 | 2012 | 337 | 0.580 |
Why?
| | Inferior Wall Myocardial Infarction | 1 | 2017 | 2 | 0.570 |
Why?
| | Heart Rupture, Post-Infarction | 1 | 2017 | 3 | 0.570 |
Why?
| | Papillary Muscles | 1 | 2017 | 15 | 0.560 |
Why?
| | Models, Cardiovascular | 4 | 2008 | 196 | 0.560 |
Why?
| | Therapy, Computer-Assisted | 2 | 2014 | 62 | 0.530 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2017 | 53 | 0.530 |
Why?
| | Aorta | 3 | 2009 | 416 | 0.520 |
Why?
| | Surgeons | 4 | 2022 | 279 | 0.520 |
Why?
| | Aortography | 1 | 2016 | 51 | 0.510 |
Why?
| | Medicare | 8 | 2023 | 740 | 0.510 |
Why?
| | Severity of Illness Index | 11 | 2021 | 2785 | 0.510 |
Why?
| | Multidetector Computed Tomography | 1 | 2016 | 33 | 0.510 |
Why?
| | Diagnostic Imaging | 3 | 2010 | 333 | 0.510 |
Why?
| | Heart Ventricles | 3 | 2018 | 782 | 0.510 |
Why?
| | Echocardiography, Stress | 1 | 2015 | 21 | 0.500 |
Why?
| | Exercise Test | 3 | 2015 | 622 | 0.490 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 48 | 0.470 |
Why?
| | Fistula | 2 | 2022 | 36 | 0.470 |
Why?
| | Consensus | 9 | 2021 | 652 | 0.470 |
Why?
| | Foreign-Body Migration | 2 | 2012 | 36 | 0.460 |
Why?
| | Radiation Injuries | 1 | 2015 | 139 | 0.450 |
Why?
| | Embolization, Therapeutic | 2 | 2007 | 209 | 0.450 |
Why?
| | Heart Septal Defects, Ventricular | 3 | 2009 | 42 | 0.450 |
Why?
| | Retrospective Studies | 22 | 2021 | 14675 | 0.450 |
Why?
| | Reoperation | 6 | 2021 | 558 | 0.450 |
Why?
| | Heart Septal Defects | 3 | 2008 | 10 | 0.450 |
Why?
| | Health Policy | 1 | 2017 | 361 | 0.440 |
Why?
| | Hospital Mortality | 11 | 2021 | 860 | 0.440 |
Why?
| | Balloon Valvuloplasty | 1 | 2013 | 5 | 0.430 |
Why?
| | Incidence | 10 | 2021 | 2657 | 0.400 |
Why?
| | Surgical Instruments | 1 | 2012 | 53 | 0.400 |
Why?
| | Reproducibility of Results | 13 | 2021 | 3069 | 0.400 |
Why?
| | Aortic Rupture | 1 | 2012 | 26 | 0.390 |
Why?
| | Coronary Disease | 5 | 2009 | 392 | 0.390 |
Why?
| | Prospective Studies | 16 | 2025 | 7131 | 0.390 |
Why?
| | Equipment Design | 6 | 2025 | 526 | 0.390 |
Why?
| | Triiodobenzoic Acids | 2 | 2011 | 11 | 0.380 |
Why?
| | Myocardial Infarction | 8 | 2008 | 1036 | 0.370 |
Why?
| | Models, Anatomic | 2 | 2009 | 94 | 0.370 |
Why?
| | Sensitivity and Specificity | 8 | 2019 | 1854 | 0.370 |
Why?
| | Adult | 30 | 2023 | 35711 | 0.370 |
Why?
| | Coronary Restenosis | 2 | 2009 | 21 | 0.370 |
Why?
| | Societies | 2 | 2013 | 38 | 0.360 |
Why?
| | Algorithms | 9 | 2010 | 1638 | 0.360 |
Why?
| | Computer Simulation | 5 | 2008 | 950 | 0.360 |
Why?
| | Heart Atria | 5 | 2012 | 130 | 0.360 |
Why?
| | Catheter Ablation | 2 | 2018 | 334 | 0.360 |
Why?
| | Cardiac Catheters | 2 | 2025 | 17 | 0.350 |
Why?
| | Angiography | 4 | 2019 | 200 | 0.350 |
Why?
| | Recurrence | 8 | 2024 | 1020 | 0.340 |
Why?
| | Meiotic Prophase I | 1 | 2009 | 2 | 0.340 |
Why?
| | Prometaphase | 1 | 2009 | 2 | 0.340 |
Why?
| | Meiosis | 1 | 2009 | 64 | 0.330 |
Why?
| | Follow-Up Studies | 14 | 2019 | 4961 | 0.330 |
Why?
| | Coronary Thrombosis | 1 | 2009 | 25 | 0.320 |
Why?
| | Angiocardiography | 1 | 2009 | 2 | 0.320 |
Why?
| | Rotation | 4 | 2011 | 118 | 0.310 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 733 | 0.310 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 70 | 0.310 |
Why?
| | Oocytes | 1 | 2009 | 180 | 0.310 |
Why?
| | Anticoagulants | 4 | 2021 | 627 | 0.310 |
Why?
| | Drug-Eluting Stents | 1 | 2009 | 65 | 0.300 |
Why?
| | Oxygen | 1 | 2013 | 919 | 0.300 |
Why?
| | Clinical Decision-Making | 4 | 2019 | 313 | 0.300 |
Why?
| | Survival Rate | 12 | 2021 | 1904 | 0.300 |
Why?
| | Migraine with Aura | 1 | 2008 | 9 | 0.300 |
Why?
| | Heart Septum | 1 | 2008 | 28 | 0.300 |
Why?
| | Stroke Volume | 2 | 2009 | 593 | 0.290 |
Why?
| | Ventricular Septum | 1 | 2007 | 9 | 0.290 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1537 | 0.290 |
Why?
| | Echocardiography, Doppler | 1 | 2008 | 111 | 0.290 |
Why?
| | Patient Simulation | 1 | 2008 | 34 | 0.290 |
Why?
| | Monitoring, Intraoperative | 1 | 2007 | 44 | 0.290 |
Why?
| | Health Status | 3 | 2021 | 756 | 0.280 |
Why?
| | Pericardium | 1 | 2007 | 55 | 0.280 |
Why?
| | Coronary Artery Bypass | 1 | 2009 | 225 | 0.270 |
Why?
| | Catheters, Indwelling | 1 | 2007 | 79 | 0.270 |
Why?
| | Hemostatic Techniques | 1 | 2007 | 46 | 0.270 |
Why?
| | Cohort Studies | 8 | 2023 | 5431 | 0.270 |
Why?
| | Hemodynamics | 6 | 2020 | 1099 | 0.270 |
Why?
| | Advisory Committees | 2 | 2018 | 231 | 0.270 |
Why?
| | Clinical Competence | 6 | 2019 | 1029 | 0.260 |
Why?
| | Wounds, Penetrating | 1 | 2007 | 67 | 0.260 |
Why?
| | Comprehension | 1 | 2008 | 169 | 0.260 |
Why?
| | American Medical Association | 1 | 2006 | 18 | 0.260 |
Why?
| | Hemorrhage | 4 | 2018 | 671 | 0.260 |
Why?
| | Equipment Failure | 3 | 2012 | 112 | 0.250 |
Why?
| | Reimbursement, Incentive | 1 | 2006 | 37 | 0.250 |
Why?
| | Patient Readmission | 4 | 2019 | 680 | 0.250 |
Why?
| | Recovery of Function | 3 | 2019 | 646 | 0.250 |
Why?
| | Aortic Diseases | 1 | 2007 | 115 | 0.250 |
Why?
| | Ischemia | 1 | 2009 | 399 | 0.250 |
Why?
| | Blood Vessel Prosthesis | 2 | 2006 | 125 | 0.250 |
Why?
| | Decompression Sickness | 2 | 2024 | 3 | 0.240 |
Why?
| | Immunoglobulin Fab Fragments | 6 | 2008 | 78 | 0.240 |
Why?
| | Ventricular Function, Left | 1 | 2009 | 530 | 0.240 |
Why?
| | Aneurysm, False | 1 | 2005 | 48 | 0.240 |
Why?
| | N-Acetylmuramoyl-L-alanine Amidase | 1 | 2004 | 8 | 0.240 |
Why?
| | Specialization | 1 | 2006 | 147 | 0.240 |
Why?
| | Aortic Aneurysm | 1 | 2005 | 64 | 0.230 |
Why?
| | Education, Medical | 1 | 2008 | 241 | 0.230 |
Why?
| | Equipment Safety | 1 | 2004 | 41 | 0.230 |
Why?
| | Medicine | 1 | 2006 | 119 | 0.230 |
Why?
| | Feasibility Studies | 2 | 2024 | 865 | 0.230 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2004 | 27 | 0.220 |
Why?
| | Healthcare Disparities | 2 | 2020 | 580 | 0.220 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2003 | 11 | 0.210 |
Why?
| | Antiphospholipid Syndrome | 1 | 2004 | 34 | 0.210 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2006 | 390 | 0.210 |
Why?
| | Magnetic Resonance Angiography | 1 | 2005 | 238 | 0.210 |
Why?
| | Automation | 2 | 2016 | 83 | 0.200 |
Why?
| | Aneurysm | 1 | 2022 | 31 | 0.200 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1294 | 0.200 |
Why?
| | Embolic Protection Devices | 1 | 2022 | 13 | 0.200 |
Why?
| | Aspirin | 3 | 2020 | 383 | 0.200 |
Why?
| | Pacemaker, Artificial | 2 | 2020 | 116 | 0.200 |
Why?
| | Hospitals, High-Volume | 2 | 2019 | 41 | 0.200 |
Why?
| | Quality of Health Care | 3 | 2019 | 611 | 0.190 |
Why?
| | Multicenter Studies as Topic | 5 | 2023 | 290 | 0.190 |
Why?
| | Arteries | 1 | 2003 | 269 | 0.190 |
Why?
| | Renal Insufficiency | 1 | 2003 | 152 | 0.190 |
Why?
| | Prognosis | 5 | 2021 | 3830 | 0.190 |
Why?
| | Observer Variation | 4 | 2011 | 324 | 0.190 |
Why?
| | Health Resources | 2 | 2019 | 122 | 0.180 |
Why?
| | Learning Curve | 2 | 2019 | 68 | 0.180 |
Why?
| | Mycobacterium tuberculosis | 1 | 2004 | 316 | 0.180 |
Why?
| | Cost-Benefit Analysis | 3 | 2019 | 621 | 0.180 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2014 | 175 | 0.170 |
Why?
| | Thromboembolism | 1 | 2021 | 106 | 0.170 |
Why?
| | Cardiovascular Agents | 3 | 2014 | 156 | 0.170 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2015 | 256 | 0.170 |
Why?
| | American Heart Association | 2 | 2019 | 311 | 0.170 |
Why?
| | Colorado | 4 | 2019 | 4471 | 0.170 |
Why?
| | Length of Stay | 4 | 2020 | 1135 | 0.170 |
Why?
| | Databases, Factual | 3 | 2020 | 1300 | 0.160 |
Why?
| | Computer Systems | 2 | 2009 | 48 | 0.160 |
Why?
| | Rural Health Services | 1 | 2020 | 110 | 0.160 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2019 | 249 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 3 | 2009 | 3380 | 0.160 |
Why?
| | Pattern Recognition, Automated | 3 | 2010 | 75 | 0.160 |
Why?
| | Hospitals, Low-Volume | 1 | 2019 | 23 | 0.160 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2019 | 58 | 0.160 |
Why?
| | Neurologists | 1 | 2019 | 21 | 0.160 |
Why?
| | Popliteal Artery | 2 | 2009 | 60 | 0.160 |
Why?
| | Anatomic Landmarks | 1 | 2019 | 28 | 0.160 |
Why?
| | Heart Valves | 1 | 2019 | 42 | 0.160 |
Why?
| | Atrioventricular Block | 1 | 2019 | 35 | 0.160 |
Why?
| | Antibodies, Monoclonal | 6 | 2008 | 1372 | 0.160 |
Why?
| | Comparative Effectiveness Research | 1 | 2020 | 152 | 0.160 |
Why?
| | Hospital Costs | 1 | 2019 | 118 | 0.160 |
Why?
| | Patient-Specific Modeling | 1 | 2019 | 39 | 0.150 |
Why?
| | Cardiopulmonary Bypass | 1 | 2020 | 194 | 0.150 |
Why?
| | Treatment Failure | 3 | 2009 | 351 | 0.150 |
Why?
| | Prisoners | 1 | 2021 | 145 | 0.150 |
Why?
| | Angioplasty, Balloon | 2 | 2011 | 90 | 0.150 |
Why?
| | Bioprosthesis | 1 | 2018 | 40 | 0.150 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2018 | 94 | 0.150 |
Why?
| | Models, Organizational | 2 | 2019 | 149 | 0.150 |
Why?
| | Software | 2 | 2016 | 616 | 0.150 |
Why?
| | Heart Block | 1 | 2018 | 41 | 0.150 |
Why?
| | Diagnostic Errors | 2 | 2010 | 164 | 0.150 |
Why?
| | Risk | 3 | 2019 | 873 | 0.140 |
Why?
| | Young Adult | 6 | 2021 | 12404 | 0.140 |
Why?
| | Proportional Hazards Models | 3 | 2019 | 1235 | 0.140 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 207 | 0.140 |
Why?
| | Disease Management | 2 | 2021 | 597 | 0.140 |
Why?
| | Intention to Treat Analysis | 2 | 2017 | 72 | 0.140 |
Why?
| | Coronary Circulation | 2 | 2007 | 138 | 0.140 |
Why?
| | Hospitals | 2 | 2024 | 641 | 0.140 |
Why?
| | Research Report | 1 | 2017 | 76 | 0.140 |
Why?
| | France | 1 | 2016 | 31 | 0.140 |
Why?
| | Single-Blind Method | 2 | 2017 | 274 | 0.130 |
Why?
| | Clinical Coding | 1 | 2016 | 20 | 0.130 |
Why?
| | Personal Satisfaction | 1 | 2018 | 200 | 0.130 |
Why?
| | Patient Safety | 2 | 2019 | 296 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 170 | 0.130 |
Why?
| | Radiologic Health | 1 | 2015 | 5 | 0.130 |
Why?
| | Delayed Diagnosis | 1 | 2016 | 81 | 0.130 |
Why?
| | Atrial Pressure | 1 | 2015 | 4 | 0.130 |
Why?
| | Atrial Function, Right | 1 | 2015 | 12 | 0.120 |
Why?
| | Valsalva Maneuver | 1 | 2015 | 10 | 0.120 |
Why?
| | Radiation Exposure | 1 | 2016 | 48 | 0.120 |
Why?
| | Netherlands | 1 | 2015 | 78 | 0.120 |
Why?
| | Movement | 2 | 2009 | 270 | 0.120 |
Why?
| | Sertoli Cells | 1 | 2015 | 24 | 0.120 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2015 | 67 | 0.120 |
Why?
| | Infertility, Male | 1 | 2015 | 62 | 0.120 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 82 | 0.120 |
Why?
| | Heart Rate | 2 | 2011 | 813 | 0.120 |
Why?
| | Adolescent | 6 | 2021 | 20374 | 0.120 |
Why?
| | Area Under Curve | 1 | 2015 | 292 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 439 | 0.120 |
Why?
| | Intersectoral Collaboration | 1 | 2015 | 61 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2016 | 183 | 0.120 |
Why?
| | Clinical Protocols | 1 | 2015 | 258 | 0.110 |
Why?
| | Fertility | 1 | 2015 | 163 | 0.110 |
Why?
| | Receptors, Androgen | 1 | 2015 | 146 | 0.110 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2014 | 28 | 0.110 |
Why?
| | Ultrasonography | 2 | 2008 | 731 | 0.110 |
Why?
| | Patient Care Team | 1 | 2019 | 612 | 0.110 |
Why?
| | Atrial Septum | 1 | 2013 | 4 | 0.110 |
Why?
| | ROC Curve | 1 | 2015 | 507 | 0.110 |
Why?
| | Punctures | 1 | 2013 | 41 | 0.110 |
Why?
| | Kidney Failure, Chronic | 1 | 2019 | 560 | 0.110 |
Why?
| | X-Rays | 2 | 2010 | 33 | 0.110 |
Why?
| | Global Health | 1 | 2016 | 320 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 506 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2020 | 902 | 0.100 |
Why?
| | Blood Vessel Prosthesis Implantation | 3 | 2004 | 201 | 0.100 |
Why?
| | Propensity Score | 3 | 2019 | 265 | 0.100 |
Why?
| | Pancreaticoduodenectomy | 1 | 2014 | 160 | 0.100 |
Why?
| | Femoral Artery | 2 | 2013 | 176 | 0.100 |
Why?
| | Forecasting | 2 | 2016 | 364 | 0.100 |
Why?
| | Age Factors | 3 | 2024 | 3153 | 0.100 |
Why?
| | Blood Pressure | 2 | 2011 | 1753 | 0.100 |
Why?
| | Models, Statistical | 1 | 2016 | 630 | 0.100 |
Why?
| | United States Food and Drug Administration | 1 | 2013 | 205 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2004 | 2028 | 0.090 |
Why?
| | Research Design | 1 | 2018 | 1052 | 0.090 |
Why?
| | Phantoms, Imaging | 4 | 2010 | 139 | 0.090 |
Why?
| | Electrocardiography | 2 | 2014 | 615 | 0.090 |
Why?
| | Europe | 2 | 2009 | 367 | 0.090 |
Why?
| | Quality Improvement | 2 | 2019 | 1111 | 0.090 |
Why?
| | Stress, Mechanical | 2 | 2003 | 470 | 0.090 |
Why?
| | Automation, Laboratory | 1 | 2010 | 7 | 0.090 |
Why?
| | Data Collection | 1 | 2013 | 654 | 0.080 |
Why?
| | Cdc20 Proteins | 1 | 2009 | 5 | 0.080 |
Why?
| | Cdh1 Proteins | 1 | 2009 | 2 | 0.080 |
Why?
| | Cyclin B1 | 1 | 2009 | 7 | 0.080 |
Why?
| | Securin | 1 | 2009 | 3 | 0.080 |
Why?
| | Anaphase-Promoting Complex-Cyclosome | 1 | 2009 | 6 | 0.080 |
Why?
| | Ubiquitin-Protein Ligase Complexes | 1 | 2009 | 8 | 0.080 |
Why?
| | Radiology, Interventional | 1 | 2010 | 31 | 0.080 |
Why?
| | Heart | 1 | 2014 | 654 | 0.080 |
Why?
| | Mitral Valve Prolapse | 1 | 2009 | 10 | 0.080 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 35 | 0.080 |
Why?
| | Hospitals, Veterans | 1 | 2011 | 265 | 0.080 |
Why?
| | Artifacts | 2 | 2009 | 124 | 0.080 |
Why?
| | Cause of Death | 3 | 2018 | 397 | 0.080 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2009 | 30 | 0.080 |
Why?
| | Equipment Failure Analysis | 1 | 2009 | 132 | 0.080 |
Why?
| | Peripheral Vascular Diseases | 1 | 2009 | 105 | 0.080 |
Why?
| | Gene Silencing | 1 | 2009 | 186 | 0.080 |
Why?
| | Ticlopidine | 1 | 2008 | 55 | 0.080 |
Why?
| | Nose | 1 | 2008 | 66 | 0.070 |
Why?
| | Prevalence | 2 | 2018 | 2576 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2019 | 5741 | 0.070 |
Why?
| | Robotics | 1 | 2009 | 90 | 0.070 |
Why?
| | PTEN Phosphohydrolase | 1 | 2009 | 158 | 0.070 |
Why?
| | Linear Models | 1 | 2010 | 826 | 0.070 |
Why?
| | Heart Failure | 2 | 2018 | 2164 | 0.070 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2005 | 23 | 0.070 |
Why?
| | Wakefulness | 1 | 2008 | 115 | 0.070 |
Why?
| | Motion | 2 | 2010 | 100 | 0.070 |
Why?
| | Leg | 1 | 2009 | 242 | 0.070 |
Why?
| | Endpoint Determination | 1 | 2008 | 77 | 0.070 |
Why?
| | Sirolimus | 1 | 2009 | 197 | 0.070 |
Why?
| | Cardiac Tamponade | 1 | 2007 | 15 | 0.070 |
Why?
| | Histone Deacetylases | 1 | 2009 | 211 | 0.070 |
Why?
| | Patient Reported Outcome Measures | 2 | 2021 | 363 | 0.070 |
Why?
| | Arthritis, Rheumatoid | 1 | 2016 | 1115 | 0.070 |
Why?
| | Injections | 1 | 2007 | 175 | 0.070 |
Why?
| | Artificial Intelligence | 2 | 2010 | 251 | 0.070 |
Why?
| | United Kingdom | 2 | 2018 | 266 | 0.070 |
Why?
| | Quality Indicators, Health Care | 2 | 2019 | 301 | 0.070 |
Why?
| | Quality of Life | 4 | 2021 | 2735 | 0.060 |
Why?
| | Thoracotomy | 1 | 2006 | 75 | 0.060 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2006 | 101 | 0.060 |
Why?
| | Cell Cycle Proteins | 1 | 2009 | 585 | 0.060 |
Why?
| | Transcription Factors | 2 | 2015 | 1649 | 0.060 |
Why?
| | Carrier Proteins | 1 | 2009 | 738 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1099 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2008 | 1878 | 0.060 |
Why?
| | Muramic Acids | 1 | 2004 | 1 | 0.060 |
Why?
| | Acetylmuramyl-Alanyl-Isoglutamine | 1 | 2004 | 11 | 0.060 |
Why?
| | Peptidoglycan | 1 | 2004 | 28 | 0.060 |
Why?
| | Ions | 1 | 2004 | 67 | 0.060 |
Why?
| | Cell Wall | 1 | 2004 | 56 | 0.060 |
Why?
| | Open Reading Frames | 1 | 2004 | 124 | 0.060 |
Why?
| | Probability | 1 | 2005 | 314 | 0.060 |
Why?
| | Pulmonary Edema | 1 | 2024 | 107 | 0.060 |
Why?
| | Whole-Body Irradiation | 1 | 2004 | 77 | 0.060 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2004 | 42 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 869 | 0.050 |
Why?
| | Shear Strength | 1 | 2003 | 68 | 0.050 |
Why?
| | Genome, Bacterial | 1 | 2004 | 137 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2004 | 536 | 0.050 |
Why?
| | Informed Consent | 1 | 2005 | 181 | 0.050 |
Why?
| | Thrombophilia | 1 | 2004 | 68 | 0.050 |
Why?
| | Thrombocytopenia | 1 | 2005 | 188 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1442 | 0.050 |
Why?
| | Catheters | 1 | 2023 | 67 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2005 | 228 | 0.050 |
Why?
| | Patient Care Planning | 1 | 2003 | 152 | 0.050 |
Why?
| | Elasticity | 1 | 2003 | 202 | 0.050 |
Why?
| | Angioplasty | 1 | 2002 | 47 | 0.050 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 8 | 0.050 |
Why?
| | Japan | 1 | 2022 | 100 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2074 | 0.050 |
Why?
| | Creatinine | 1 | 2003 | 491 | 0.050 |
Why?
| | Patient-Centered Care | 1 | 2006 | 506 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 372 | 0.050 |
Why?
| | Curriculum | 1 | 2008 | 929 | 0.050 |
Why?
| | Base Sequence | 1 | 2004 | 2162 | 0.040 |
Why?
| | Acute Disease | 1 | 2003 | 981 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1028 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 2021 | 128 | 0.040 |
Why?
| | Escherichia coli | 1 | 2004 | 786 | 0.040 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2024 | 242 | 0.040 |
Why?
| | Patient Discharge | 2 | 2004 | 866 | 0.040 |
Why?
| | Florida | 1 | 2020 | 96 | 0.040 |
Why?
| | Child | 2 | 2012 | 20961 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 343 | 0.040 |
Why?
| | Naltrexone | 1 | 2021 | 86 | 0.040 |
Why?
| | Computational Biology | 1 | 2004 | 600 | 0.040 |
Why?
| | Population Density | 1 | 2020 | 93 | 0.040 |
Why?
| | Delayed-Action Preparations | 1 | 2021 | 179 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2854 | 0.040 |
Why?
| | Prisons | 1 | 2021 | 85 | 0.040 |
Why?
| | Norepinephrine | 1 | 2001 | 218 | 0.040 |
Why?
| | Travel | 1 | 2020 | 123 | 0.040 |
Why?
| | Mice | 3 | 2015 | 16832 | 0.040 |
Why?
| | Epinephrine | 1 | 2001 | 180 | 0.040 |
Why?
| | Cost Savings | 1 | 2019 | 83 | 0.040 |
Why?
| | Decision Making | 1 | 2006 | 842 | 0.040 |
Why?
| | Cardiac Care Facilities | 1 | 2019 | 13 | 0.040 |
Why?
| | Narcotic Antagonists | 1 | 2021 | 163 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2021 | 564 | 0.040 |
Why?
| | Cardiac Imaging Techniques | 1 | 2019 | 21 | 0.040 |
Why?
| | Trauma Severity Indices | 1 | 2019 | 109 | 0.040 |
Why?
| | Credentialing | 1 | 2019 | 18 | 0.040 |
Why?
| | Terminology as Topic | 1 | 2020 | 204 | 0.040 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2001 | 320 | 0.040 |
Why?
| | Models, Econometric | 1 | 2018 | 36 | 0.040 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2019 | 96 | 0.040 |
Why?
| | Renin-Angiotensin System | 1 | 2018 | 82 | 0.040 |
Why?
| | Risk Management | 1 | 2018 | 92 | 0.040 |
Why?
| | Markov Chains | 1 | 2018 | 126 | 0.040 |
Why?
| | Reference Values | 1 | 2019 | 793 | 0.040 |
Why?
| | Inpatients | 2 | 2016 | 462 | 0.040 |
Why?
| | Residence Characteristics | 1 | 2020 | 330 | 0.040 |
Why?
| | Child, Preschool | 1 | 2012 | 10514 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2107 | 0.030 |
Why?
| | Workload | 1 | 2019 | 154 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2018 | 134 | 0.030 |
Why?
| | Quality Assurance, Health Care | 1 | 2019 | 320 | 0.030 |
Why?
| | Altitude | 1 | 2001 | 451 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 310 | 0.030 |
Why?
| | General Practice | 1 | 2016 | 28 | 0.030 |
Why?
| | Morula | 1 | 2015 | 3 | 0.030 |
Why?
| | Blastocyst | 1 | 2015 | 48 | 0.030 |
Why?
| | Spermatogenesis | 1 | 2015 | 62 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1293 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2019 | 553 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2019 | 425 | 0.030 |
Why?
| | Biomarkers | 1 | 2006 | 3923 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2016 | 218 | 0.030 |
Why?
| | Infertility, Female | 1 | 2015 | 106 | 0.030 |
Why?
| | Animals | 3 | 2015 | 35076 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1555 | 0.030 |
Why?
| | Karnofsky Performance Status | 1 | 2014 | 39 | 0.030 |
Why?
| | Medicaid | 1 | 2018 | 448 | 0.030 |
Why?
| | Spatio-Temporal Analysis | 1 | 2014 | 27 | 0.030 |
Why?
| | Duodenal Neoplasms | 1 | 2014 | 22 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2016 | 283 | 0.030 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 277 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1980 | 0.030 |
Why?
| | Radiation | 1 | 2013 | 25 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 921 | 0.030 |
Why?
| | Bile Duct Neoplasms | 1 | 2014 | 99 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2015 | 495 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 231 | 0.020 |
Why?
| | Combined Modality Therapy | 2 | 2005 | 1219 | 0.020 |
Why?
| | Torsion, Mechanical | 1 | 2009 | 6 | 0.020 |
Why?
| | Laparoscopy | 1 | 2014 | 456 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2010 | 124 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 647 | 0.020 |
Why?
| | Exercise | 1 | 2001 | 1941 | 0.020 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2009 | 26 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 132 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2009 | 160 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1415 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2016 | 979 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 137 | 0.020 |
Why?
| | Posture | 1 | 2009 | 175 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 4106 | 0.020 |
Why?
| | Radiography | 1 | 2010 | 874 | 0.020 |
Why?
| | Myocardial Ischemia | 1 | 2008 | 256 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 962 | 0.020 |
Why?
| | Vascular Surgical Procedures | 1 | 2009 | 295 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2009 | 786 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 892 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2009 | 664 | 0.020 |
Why?
| | Binding Sites | 1 | 2009 | 1252 | 0.020 |
Why?
| | Platelet Count | 1 | 2005 | 83 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 5365 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2009 | 1711 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1207 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 379 | 0.010 |
Why?
| | Sex Distribution | 1 | 2005 | 361 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2786 | 0.010 |
Why?
| | Patient Admission | 1 | 2004 | 186 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2120 | 0.010 |
Why?
| | Odds Ratio | 1 | 2005 | 1027 | 0.010 |
Why?
| | Myocardial Reperfusion | 1 | 2002 | 52 | 0.010 |
Why?
| | Postoperative Care | 1 | 2003 | 246 | 0.010 |
Why?
| | Heparin | 1 | 2003 | 252 | 0.010 |
Why?
| | Signal Transduction | 1 | 2015 | 4930 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2003 | 521 | 0.010 |
Why?
| | Prazosin | 1 | 2001 | 27 | 0.010 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2001 | 30 | 0.010 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2001 | 34 | 0.010 |
Why?
| | Phenylephrine | 1 | 2001 | 75 | 0.010 |
Why?
| | Health Care Costs | 1 | 2003 | 407 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2001 | 680 | 0.010 |
Why?
|
|
Carroll's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|